Freedom Capital Markets has lowered its price target for Li Auto (NASDAQ: LI) from $34 to $25, citing a mixed quarterly performance and a challenging outlook as China's electric vehicle sector grapples with a fierce price war and softening demand.
Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
Investment bank Macquarie has lowered its price target for Chinese EV maker XPeng, pointing to reduced government subsidies and a complex path to profitability as the company expands its model lineup.
Investment bank Macquarie has raised its rating on NIO Inc. (NYSE:NIO) from Neutral to Outperform, citing better-than-expected fourth-quarter delivery figures and the growing success of its battery subscription model. The firm also increased its price target to $6.10.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
UBS has increased its price target for digital transformation leader Globant to $75, forecasting a period of stabilized, if modest, growth for the IT services sector next year despite near-term revenue headwinds.
Analyst firm Stifel has initiated coverage on sports data giant Genius Sports with a Hold rating, praising its foundational role in the online betting ecosystem but flagging a balanced risk-reward at current levels.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Despite a recent price target cut by KeyBanc, On Holding AG (NYSE: ONON) remains a top growth pick for 2026, with Goldman Sachs upgrading the stock to Buy. Analysts highlight the brand's global momentum and product strength as key drivers.
Truist Securities has raised its price target for Amer Sports (NYSE: AS), citing the company's clear long-term roadmap and 'durable growth levers' across its portfolio of iconic sports brands. The firm sees a realistic path to earnings per share exceeding $2.50 by fiscal 2030.
Despite a recent 6.8% pullback, AUTO1 Group SE (ETR:AG1) has delivered a staggering 239% return to its shareholders over the past three years, highlighting the potential rewards of holding through market volatility. We examine the underlying business trends and investor sentiment behind the numbers.
As demand for specialist education soars, private investors—from Abu Dhabi to private equity firms—are capitalizing on a strained system, drawing criticism for extracting profits from vulnerable children and cash-strapped councils.
A growing number of pensioners are being drawn into the self-assessment tax system as frozen thresholds clash with rising state pension payments. This guide explains who needs to file, key deadlines, and strategies to protect your retirement income.
With the annual self-assessment deadline a perennial source of stress for freelancers and sole traders, this guide breaks down the essentials of income tax and National Insurance. The landscape is set for a significant shift with the incoming Making Tax Digital regime, making this a crucial year to get to grips with the current rules.
Despite bearing the brunt of costly natural disasters, Asia-Pacific remains the world's least insured region, with a staggering $64 billion protection shortfall in 2024 alone, threatening economic stability and vulnerable communities.
Chinese regulators have conditionally approved leading AI startup DeepSeek to purchase Nvidia's advanced H200 artificial intelligence chips, sources tell Reuters, as Beijing navigates competing pressures to advance its tech sector while managing geopolitical tensions.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
